Showing posts with label inflammatory bowel disease. Show all posts
Showing posts with label inflammatory bowel disease. Show all posts

Friday, 14 September 2012

Gut microbes and health

I'd like to apologise to my Gutness Gracious Me blog. I've neglected you and your subscribers for quite a few months now and I'm sorry. I have no excuse so please accept my humble apology.

Friends again?

OK. There's been quite a bit of new research come out in the intervening months which I need to catch up on. For this entry I'm going to list a couple of interesting papers showing how, if it was ever needed, gut bacteria really are starting to be taken quite seriously in lots of science circles.

Nature is a good starting point (the journal Nature not nature in general). A whole supplement was recently dedicated to gut bacteria which can be viewed here. Unfortunately the papers aren't open-access but I might draw your attention to two of them in particular:


Next up is another Nature journal, Nature Neuroscience, which carried an interesting piece by Cryan & Dinan***** on the potential 'mind-altering' effects of gut bacteria and everyone's favourite term: the gut-brain axis. I've kinda done bacteria potentially influencing behaviour before on a sister blog entry (see here) so don't really want to rehash that again. Suffice to say that as well as being home to quite a lot of bacteria, our gut also houses quite a few neurotransmitters and their receptors more traditionally associated with brain, so why would we expect these not to potentially serve functions other than controlling gut motility and the like. Whether there is interaction between these neurotransmitters and gut bacteria.... well I'd speculate there might very well be.

----------

* Tremaroli V. & Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012; 489: 242-249.

** Semova I. et al. Microbiota regulate intestinal absorption and metabolism of fatty acids in the zebrafish. Cell Host & Microbe. 2012; 12: 277-288.

*** Maynard CL. et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 489: 231-241.

**** Cucchiara S. et al. Interactions between intestinal microbiota and innate immune system in pediatric inflammatory bowel disease. Journal of Clinical Gastroenterology. 2012; 46: S64-S66.

***** Cryan JF. & Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nature Reviews: Neuroscience. September 2012.

Monday, 13 February 2012

Plasma amino acids and inflammatory bowel disease

My recent post on the application of metabolomics to food fingerprinting got me thinking about the examination of biological fluids and how our metabolome might have some interesting secrets to one day share. The 'promise' of the science of metabolomics is that one day, we should be able to look at various biological fluids across a range of conditions and based on the compounds excreted/detected determine diagnosis, disease progression and how well someone responds to intervention. I hasten to add that we are nowhere near that position yet.

In light of this, it was perhaps inevitable ('it is your destiny') that this paper by Hisamatsu and colleagues* (full-text) on possible plasma biomarkers for inflammatory bowel disease (IBD) would get some attention. I'm pretty sure that I don't have to explain this to viewers but the term inflammatory bowel disease covers quite a bit of diagnostic ground including Crohn's disease and ulcerative colitis. Diagnostic confirmation of these conditions is quite a complicated process normally involving a combination of peripheral measures (blood tests, stool analysis) coupled with more direct observation of the bowel.

Hisamatsu and colleagues reported that a previously trialed network analysis of plasma amino acid levels in patients diagnosed with IBD might provide novel, non-invasive and importantly, objective biomarkers potentially opening up some new research areas into the nature of IBDs.

The details:

  • Fasting plasma 'aminograms' for a discovery group of 102 Japanese adult patients diagnosed with Crohn's disease (CD) and 102 patients with ulcerative colitis (UC) were initially compared against 102 healthy control participants. The majority of participants were male (70%) with disease duration ranging between an average of 7.8-11 years. A minority of participants were described as having 'active' disease (CD = 29/102; UC = 38/102).  Obtained aminogram results were also validated using a validation set of participants (CD: n=63; UC: n=120; controls: n=108).
  • Serum albumin levels were reported as significantly lower in the IBD groups compared to controls.
  • Various differences were noted between the groups in terms of amino acid levels. The authors seemed to have concentrated on histidine and tryptophan as primary examples with a view to disease activity and correlation with C-reactive protein levels (a marker for inflammation).
  • Implementing their network analysis (MIAI), the authors came up with a formula based on 6 amino acids which discriminated CD and UC groups from controls with ROC values ranging from 0.894 to 0.955 depending on whether the discovery or validation group were used and comparing across the IBDs with controls. 
  • Depending on whether disease was active or in remission, a formula incorporating data for 7 amino acids was suggested to have some power in discriminating disease activity with ROC values ranging from 0.894 (CD active vs. CD remission) and 0.849 (UC active vs. UC remission).

The data produced by this study is interesting. OK, it is not totally 'diagnostic' either in terms of classifying IBD from controls or looking at active vs. remissive symptom presentation but it's not a bad start at all. Indeed the use of discovery and training sets takes me back to a wonderful paper covered last year on schizophrenia, which did find a perfect classification based on a handful of serum and urinary markers. It makes me wonder if they were looking at serum and urine at the same time or maybe incorporating a few more well-known markers, whether those ROC values might further approach the magical number 1 (denoting a perfect classification).

The use of statistical models allied to biochemical data is also interesting. I note that similar linkages have been used in other areas of medicine, possibly even to recreate speech from brain activity...?

* Hisamatsu T. et al. 2012 Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease. PLoS ONE. January 2012
DOI: 10.1371/journal.pone.0031131

Tuesday, 20 December 2011

Diagnosis by gut bacteria?

Please don't take the title of this post too literally. Sciences is only just beginning to unravel the first strands of the complicated universe that is our gut microbiota but two recent papers certainly do make for some interesting reading.

The first paper by Iebba and colleagues* provides quite a nice summary of where we stand (research-wise) with regards to different bacterial species seemingly predominating in different childhood conditions. The second paper by Jeffery and colleagues** details the intriguing possibility that irritable bowel syndrome (IBS), or some phenotypes of IBS based on the presence of functional bowel disturbances, might be classifiable by the predominating types of gut bacteria.

The Iebba paper was of double (triple) interest to me because it mentioned autism, coeliac disease (CD) and inflammatory bowel disease (IBD) in the same sentence. In particular, the prevalence of Bacteroidetes alongside a parallel decrease of Firmicutes was a commonality between these three conditions; the first time I've seen a research group looking (bacterially) at these conditions together. I have to point out that autism is an extremely heterogeneous condition with quite a lot of scope for comorbidity; hence I am careful with any generalisations.

By contrast the Jeffery paper, although based on quite a small participant group, suggested quite a few things including that cluster analysis might be able to 'pick out' those cases of IBS associated with diarrhoea compared with those where constipation or alternating bowel habits were more common. Interestingly, their analysis also reported the opposite trend in terms of an increase of Firmicutes-associated taxa and a depletion of Bacteroidetes-related taxa in some of their participant cases. This alongside other related findings which perhaps indicate that the so-called 'leaky gut' (gut hyperpermeability) might also show some differences in terms of site when sub-categorising IBS on the basis of predominant functional bowel patterns.

Aside from factors such as different ages, different populations, different genders, et al, all of this makes me wonder about things like the immune system differences between conditions like IBD and CD compared with IBS. Indeed a few open questions: do the gut bacteria findings in autism perhaps reflect similar immune features to CD and IBD or is it all merely a coincidence? Is IBS an immune-mediated condition the same way as CD or IBD are or are other forces at work?

Without getting too Arthur C. Clarke, there are lots of potential possibilities to these collected works based on our individual and collected patterns of gut microbiota. Unlike fingerprints or retinal scans, gut bacteria is perhaps slightly more dynamic as a function of diet, environment, etc. and so is probably not going to be biometrically encoded onto your passport any time soon. Having said that, if the subtle differences between our gut bacteria might also be reflective of our condition or disease, this could potentially offer some quite startling insights into the way medicine diagnoses and also manages a wide variety of conditions.

Finally, this is probably my last post on this blog until the New Year. I would like to wish readers Merry Christmas and a Happy New Year. I raise a glass of water to your good digestive health over the holiday period!

* Iebba V. et al. Gut microbiota and pediatric disease. Digestive Diseases. December 2011.

** Jeffery IB. et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. December 2011.

Tuesday, 15 November 2011

Crohn's disease and the LOFFLEX diet

A short post this one following a very interesting series airing here in the UK called the Food Hospital. 'Let food be your medicine' was the mantra of a certain Greek gentleman called Hippocrates (or perhaps according to Bill and Ted, 'Hippo-crates') and that is exactly what this series is suggesting.

In the programmes so far we have seen conditions ranging from migraine to obesity discussed. Tonight's programme featured a particularly brave young woman called Laura who presented with quite a serious case of Crohn's disease. For those who want more information about Crohn's see here. The long and short of it is inflammation, discomfort and quite a few 'peripheral' symptoms; no recognised cure and a life of medication and possibly surgery. Certainly one of the more serious gastrointestinal (GI) conditions.

Anyhow true to the name, the Food Hospital investigated whether it was possible the manage some of the symptoms of Crohn's disease through dietary changes. The plan in question is highlighted here and included a 3-step dietary intervention beginning with a cessation of food intake and reliance instead on a liquid feed containing all the necessary nutrients, followed a few weeks later by the implementation of the LOFFLEX (LOw Fibre, Fat Limited EXclusion) diet finally followed by dietary challenge/rechallenge in the hope of identifying problem foods related to symptoms.

It was interesting to see that some success was reported whilst on the regime in terms of symptom reduction following a flare-up. This is not proof of anything but certainly an interesting case study (n=1). Looking at the scientific literature for the LOFFLEX diet, things seem to be a little bit sparse at the moment. I found this trial from Addenbrookes Hospital which was the first place to look at the diet (I think). I also noted an interesting name on the authorship list, Prof. John Hunter, who is quite an expert on all things gastroenterology and particularly a role for gut bacteria in various bowel conditions.

I await more research on this very interesting regime and its potential applications to other conditions.